Clinical Trial Update: Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults [Phase 4]

View source ↗

Summary

Phase 4 study assessing immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) in HIV-infected adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Streptococcal Pneumonia

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Streptococcal Pneumonia, HIV/AIDS | Phase 4 | Status: COMPLETED